Reaction

Chemotherapy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,657 reports · 73 co-occurring drugs

As of the last recalculation, Chemotherapy appears in 3,657 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 72.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pancrelipase	435	72.7	73.5
Venetoclax	213	20.8	20.9
Abiraterone Acetate	97	13.8	13.8
Risankizumab-Rzaa	136	9.8	9.8
Fosaprepitant Dimeglumine	19	7.9	7.9
Ibrutinib	105	7.6	7.6
Bosentan	59	6.8	6.8
Pegfilgrastim	112	6.6	6.6
Aprepitant	21	6.5	6.5
Doxorubicin Hydrochloride	33	5.8	5.8
Macitentan	67	5.6	5.6
Esketamine Hydrochloride	17	5.4	5.5
Voclosporin	8	5.3	5.3
Epoprostenol	12	5.2	5.2
Abiraterone	12	5.0	5.0
Upadacitinib	67	4.7	4.7
Selexipag	21	4.6	4.7
Human Insulin	10	4.6	4.6
Atovaquone	6	4.2	4.2
Romiplostim	11	4.2	4.2
Azacitidine For	13	4.1	4.1
Ranolazine	7	3.8	3.8
Golimumab	56	3.8	3.8
Sildenafil Powder,	23	3.7	3.7
Glecaprevir And Pibrentasvir	7	3.6	3.6
Fondaparinux Sodium	5	3.5	3.5
Ambrisentan	75	3.5	3.5
Azacitidine	18	3.5	3.5
Mesna Injection	5	3.4	3.4
Mesna	5	3.4	3.4
Tenofovir Disoproxil Fumarate Tablets	5	3.3	3.3
Darbepoetin Alfa	31	3.3	3.3
Granisetron Hydrochloride	6	3.3	3.3
Granisetron	6	3.3	3.3
Posaconazole	9	3.2	3.2
Irinotecan Hydrochloride	7	3.1	3.1
Doxorubicin	48	3.1	3.1
Prochlorperazine Maleate	5	3.1	3.1
Pembrolizumab	56	3.1	3.1
Olaparib	11	3.0	3.0
Riociguat	17	3.0	3.0
Denosumab	103	2.9	3.0
Lanreotide Acetate	4	2.9	2.9
Conjugated Estrogens And Medroxyprogesterone Acetate	12	2.9	2.9
Docetaxel Anhydrous	34	2.9	2.9
Docetaxel	34	2.9	2.9
Fluticasone Propionate And Salmeterol	20	2.7	2.7
Cisplatin	37	2.7	2.7
Adalimumab	309	2.6	2.6
Brivaracetam	4	2.5	2.5
Belimumab	14	2.5	2.5
Apalutamide	5	2.4	2.4
Tadalafil	42	2.4	2.4
Umeclidinium Bromide And Vilanterol Trifenatate	7	2.4	2.4
Ifosfamide	9	2.4	2.4
Blinatumomab	4	2.2	2.2
Ustekinumab	39	2.2	2.2
Leuprolide Acetate	29	2.1	2.1
Droxidopa	8	2.1	2.1
Romosozumab-Aqqg	5	2.1	2.1
Patiromer	5	2.1	2.1
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	14	1.9	1.9
Temozolomide	7	1.9	1.9
Clozapine	40	1.8	1.8
Medroxyprogesterone Acetate	13	1.5	1.5
Lenvatinib	8	1.4	1.4
Osimertinib	7	1.2	1.2
Guselkumab	7	1.1	1.1
Aflibercept	6	1.1	1.1
Bimekizumab	4	1.1	1.1
Evolocumab	24	0.8	0.8
Apremilast	20	0.8	0.8
Dupilumab	60	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.